Silibinin Powder CAS 22888-70-6

Silibinin powder is a flavonoid lignan compound isolated from the seeds of the Asteraceae plant Silybin purpurea. Its main active ingredients include four isomers: Silybin, Isosilybin, Silybin, and Silybin. It can prevent damage to the liver caused by chemical toxins, food toxins, and drugs, promote liver cell regeneration and repair, and is known as a "natural liver protective drug". At room temperature, it is a white crystalline powder, odorless, slightly bitter in taste, with hygroscopicity. It is easily soluble in acetone, ethyl acetate, methanol, ethanol, slightly soluble in chloroform, and almost insoluble in water. Silymarin, also known as heparin, milk thistle, total flavonoids of silymarin, silymarin, Yiganling, silymarin, and ligaron, was used by ancient Chinese people to treat liver and gallbladder disases as early as 20 years ago in the Clinical studies have shown that it has a significant protective and stable effect on the liver cell membrane; It has varying degrees of protective and therapeutic effects on various types of liver damage caused by liver toxins such as carbon tetrachloride, thioacetamide, muscarine, ghouline, and pig excrement alkaloid, and has a certain inhibitory effect on the increase of alanine aminotransferase caused by carbon tetrachloride. Suitable for the treatment of chronic persistent hepatitis, chronic active hepatitis, early cirrhosis, liver poisoning, and other disases. In addition, this product also has strong antioxidant properties, which can eliminate free radicals in the human body and delay aging. It has been widely used in fields such as medicine, health products, food, and cosmetics.

Silibinin powder, a natural flavonoid lignan extracted from the Asteraceae plant Silymarin, has become one of the core drugs in the global field of liver disease treatment due to its multi-target hepatoprotective effects and low toxicity characteristics. Its mechanism of action covers five dimensions: antioxidant, anti-inflammatory, anti fibrosis, detoxification, and immune regulation. It plays a key therapeutic role in liver disases such as acute and chronic hepatitis, fatty liver, drug-induced liver injury, alcoholic liver disease, and cirrhosis.

Core pharmacological mechanism: Five dimensional hepatoprotective network

 

1. Construction of antioxidant defense system
Silymarin forms a dual antioxidant barrier by scavenging free radicals and inhibiting lipid peroxidation. The phenolic hydroxyl groups in its structure can directly react with reactive oxygen species (ROS) such as superoxide anions (O ₂⁻) and hydroxyl radicals (· OH), while upregulating the activity of glutathione (GSH) synthase, resulting in a 40% -60% increase in GSH levels in liver cells. Clinical studies have shown that in patients with non-alcoholic steatohepatitis (NASH), treatment with silibinin for 12 weeks resulted in a 32% decrease in serum malondialdehyde (MDA) levels and a 25% increase in GSH/GSSG ratio, significantly improving oxidative stress status.

 

2. Regulation of anti-inflammatory signaling pathway
Silymarin blocks the inflammatory cascade by inhibiting the NF - κ B and MAPK pathways. In the CCl ₄ - induced liver fibrosis model, silibinin can reduce the expression of pro-inflammatory factors such as TNF - α and IL-6 by 60% -70%, while promoting the secretion of anti-inflammatory factors such as IL-10. For patients with alcoholic liver disease, after 8 weeks of treatment with silymarin combined with metoprolol, ALT levels decreased by 55%, AST levels decreased by 48%, and the inflammatory activity score (HAI) improved by 72%.

 

3. Anti fibrotic therapy targets
Silymarin blocks the progression of liver fibrosis through a dual mechanism:

Inhibition of hepatic stellate cell activation: Downregulation of fibrosis markers such as α - SMA and Collagen I expression. In a rat model of liver fibrosis induced by bile duct ligation, silibinin can reduce fibrosis area by 58%.
Promote matrix metalloproteinase (MMP) expression: Upregulate MMP-2 and MMP-9 activity, accelerate extracellular matrix (ECM) degradation. Clinical research shows that in patients with post hepatitis B cirrhosis, after 24 weeks of silibinin treatment, the liver hardness value (LSM) decreased by 22%, and the Child Pugh score improved by 65%.

 

4. Enhanced detoxification function
Silymarin enhances the liver's metabolic capacity for drugs, alcohol, and environmental toxins by inducing the expression of phase II detoxifying enzymes such as GST and UGT. In patients with liver injury induced by anti tuberculosis drugs such as isoniazid and rifampicin, silibinin can reduce serum total bilirubin (TBIL) levels by 40%, shorten prothrombin time (PT) by 2.5 seconds, and significantly reduce the incidence of drug-induced liver injury.

5. Optimization of immune regulatory network
Silymarin improves the immune status of patients with autoimmune hepatitis (AIH) by regulating Th1/Th2 balance and inhibiting T cell activation. In AIH model mice, silibinin can reduce serum IgG levels by 35%, increase the proportion of CD4 ⁺ CD25 ⁺ regulatory T cells in the spleen by 28%, and significantly alleviate liver inflammation infiltration.

Clinical indication: Treatment of liver diseases across the entire spectrum

 

1. Adjuvant therapy for viral hepatitis
Chronic hepatitis B/hepatitis C: Silibinin powder combined with nucleoside (acid) analogs (such as entecavir) or direct antiviral drugs (DAAs) can accelerate the negative conversion of HBV DNA or HCV RNA, and improve liver inflammation and fibrosis. The study showed that among HBeAg positive chronic hepatitis B patients, the negative rate of HBV DNA in the silibinin combined treatment group at 6 months was 18% higher than that in the single drug group, and the improvement rate of liver inflammatory activity score (Ishak) was 75%.
Acute viral hepatitis: Silymarin can shorten the time for jaundice resolution (average 3.2 days) and accelerate the recovery of ALT/AST to normal (average 5.7 days earlier).

 

2. Management of non-alcoholic fatty liver disease (NAFLD)
Simple fatty liver: Silymarin reduces liver fat content by regulating the expression of lipid metabolim related genes such as PPAR - α and SREBP-1c. In NAFLD patients, after 24 weeks of treatment with silibinin, the hepatic steatosis score (CAP value) decreased by 42% and the insulin resistance index (HOMA-IR) decreased by 30%.
NASH progression blockade: Silymarin can inhibit hepatocyte ballooning and Mallory body formation in NASH patients, resulting in a decrease of ≥ 2 points in NASH activity score (NAS) in 68% of patients.

 

3. Intervention for alcoholic liver disease (ALD)
Alcoholic fatty liver: Silymarin accelerates alcohol metabolim by upregulating the activities of alcohol dehydrogenase (ADH) and aldehyde dehydrogenase (ALDH). Among long-term drinkers, silibinin can reduce serum gamma GT levels by 50% and decrease liver fat infiltration area by 45%.
Alcoholic hepatitis: Silymarin combined with glucocorticoid treatment can reduce the 28 day mortality rate of patients with severe alcoholic hepatitis (from 40% to 25%), while improving the Maddrey discriminant function score.
4. Prevention and treatment of drug-induced liver injury (DILI)
Chemotherapy related liver injury: In patients with breast cancer undergoing chemotherapy, silibinin can reduce the incidence of ALT elevation after chemotherapy from 32% to 15%, and the incidence of severe liver injury (≥ grade 3) from 12% to 4%.

 

Anti tuberculosis drug induced liver injury: Prophylactic administration of silibinin can reduce the incidence of liver injury during anti tuberculosis treatment from 28% to 9%, significantly improving treatment compliance.

5. Management of complications in liver cirrhosis
Portal hypertension: Silymarin reduces the risk of esophageal variceal bleeding in patients with cirrhosis by 30% by reducing liver stiffness and improving sinusoidal endothelial cell function.
Hepatic encephalopathy: Silymarin can regulate intestinal microbiota, reduce ammonia production, and improve the neuropsychological test scores of patients with mild hepatic encephalopathy by up to 60%.

Synthetic silibinin powder: the high-purity silybin content is 97%~101%. The preparation method is to use silymarin shell as raw material and add ethyl acetate to water Dissolve the silybin shell, extract the total flavonoids, collect ketones in vacuum, and then dissolve, extract, filter and dry the total flavonoids to obtain the high-purity silybin.

Two common Silibinin laboratory synthesis methods are introduced as follows:

Silibinin powder can stabilize the liver cell membrane, maintain the integrity of liver cells, make the toxin unable to penetrate and destroy the liver, and accelerate the synthesis of DNA (deoxyribonucleic acid) of liver cells. It can prevent liver cirrhosis, fatty liver, cholangitis, psoriasis and other disases. At the same time, it can inhibit the growth and differentiation of liver cancer, prostate cancer, breast cancer and cervical cancer cells. It is the flavonoid with the most curative effect on liver disases found in the world at present. 

Pharmacological action: silybin is a flavonoid compound extracted and isolated from the fruit of Silybum marianum, a chrysanthemum plant. It has an obvious effect of protecting and stabilizing the membrane of liver cells, can improve liver function, produce enzyme reducing effect, and is not easy to cause enzyme rebound. Silybin can stabilize the liver cell membrane and maintain its integrity, promote the ultrastructural recovery of liver cells, promote the division and growth of normal liver cells, improve the ability of liver cells to synthesize RNA and protein, improve the ability of reticuloendothelial system to produce macrophages, strengthen the activity of macrophages, and accelerate the clearance of viruses. At the same time, silybin can promote fat transfer and antioxidant effect, prevent fat from excessive oxidation and infiltration, and reduce liver steatosis; It can also promote the metabolic function of the liver, enhance its detoxification, and reduce the damage of toxins to hepatocytes. Therefore, silybin has the effect of protecting normal liver cells and promoting the recovery of damaged cell membranes.

Pharmacokinetics: silybin was excreted about 8% of the dosage 48 hours after intravenous injection. About 20% of the dose was excreted 48 hours after oral administration, of which about 80% was excreted by bile in the form of metabolites, and most of the rest was excreted in prototype.

Hot Tags: silibinin powder cas 22888-70-6, suppliers, manufacturers, factory, wholesale, buy, price, bulk, for sale, larocaine hydrochloride, phenacetin crystal, Tetracaine hydrochloride powder, pure aspirin powder, benzocaine 200mesh, Xylazine hcl